Risk factors for levofloxacin resistance in Stenotrophomonas maltophilia from respiratory tract in a regional hospital
Journal
Journal of Microbiology, Immunology and Infection
Journal Volume
48
Journal Issue
3
Pages
291-295
Date Issued
2015
Author(s)
Abstract
Objectives: Stenotrophomonas maltophilia is a bacterial pathogen associated with health-care associated infections, particularly in immunocompromised patients. Members of the fluoroquinolone drug class are frequently used to treat S. maltophilia infection; however, S. maltophilia resistance to fluoroquinolones, especially levofloxacin, has been increasing. Methods: We sought to identify risk factors associated with levofloxacin resistance using a case-control study. We examined sputum from 76 S. maltophilia-positive patients admitted to our hospital between January 1, 2010 and June 30, 2011. Case groups were defined as patients who had S. maltophilia infections resistant to levofloxacin, and control groups were defined as patients who had S. maltophilia infections susceptible to levofloxacin treatment. Patient information including demographics, previous antibiotic use, and other traits were recorded. In addition, S. maltophilia isolates from patient sputum were assessed for antibiotic resistance as well as for the presence of genes associated with drug resistance. Results: Previous antibiotic treatment with first- or second-generation cephalosporin was found more often in the levofloxacin-susceptible group; by contrast, previous piperacillin/tazobactam treatment occurred more often in the levofloxacin-resistant group. Three genes associated with drug resistance, including SmeA, SmeD, and SpgM were not significantly different between these groups. Conclusion: Piperacillin/tazobactam treatment is associated with subsequent isolation of levofloxacin-resistant S. maltophilia from the respiratory tract. ? 2013, Taiwan Society of Microbiology.
Subjects
Levofloxacin; Microbial sensitivity tests; Risk factors; Stenotrophomonas maltophilia
SDGs
Other Subjects
antibiotic agent; cephalosporin; levofloxacin; phosphoglucomutase; piperacillin plus tazobactam; antiinfective agent; levofloxacin; penicillanic acid; piperacillin; piperacillin, tazobactam drug combination; adult; aged; antibiotic resistance; antibiotic sensitivity; antibiotic therapy; Article; bacterial infection; bacterium isolation; case control study; clinical assessment; clinical evaluation; controlled study; disease association; female; genetic resistance; high risk patient; hospital admission; human; infection resistance; infection risk; major clinical study; male; patient information; respiratory system; respiratory tract infection; risk assessment; risk factor; sputum analysis; sputum culture; Stenotrophomonas maltophilia; stenotrophomonas maltophilia infection; analogs and derivatives; antibiotic resistance; cross infection; drug effects; drug utilization; Gram-Negative Bacterial Infections; hospital; isolation and purification; microbiology; Respiratory Tract Infections; sputum; Stenotrophomonas maltophilia; very elderly; Aged; Aged, 80 and over; Anti-Bacterial Agents; Case-Control Studies; Cross Infection; Drug Resistance, Bacterial; Drug Utilization; Female; Gram-Negative Bacterial Infections; Hospitals; Humans; Levofloxacin; Male; Penicillanic Acid; Piperacillin; Respiratory Tract Infections; Risk Factors; Sputum; Stenotrophomonas maltophilia
Publisher
Elsevier Ltd
Type
journal article